Double blind, randomized, placebo controlled clinical trial for the treatment of diabetic foot ulcers, using a nitric oxide releasing patch: PATHON

Sandra Y Silva, Ligia C Rueda, Gustavo A Márquez, Marcos López, Daniel J Smith, Carlos A Calderón, Juan C Castillo, Jaime Matute, Christian F Rueda-Clausen, Arturo Orduz, Federico A Silva, Piyaporn Kampeerapappun, Mahesh Bhide, Patricio López-Jaramillo, Sandra Y Silva, Ligia C Rueda, Gustavo A Márquez, Marcos López, Daniel J Smith, Carlos A Calderón, Juan C Castillo, Jaime Matute, Christian F Rueda-Clausen, Arturo Orduz, Federico A Silva, Piyaporn Kampeerapappun, Mahesh Bhide, Patricio López-Jaramillo

Abstract

Background: Diabetes Mellitus constitutes one of the most important public health problems due to its high prevalence and enormous social and economic consequences. Diabetic foot ulcers are one of the chronic complications of diabetes mellitus and constitute the most important cause of non-traumatic amputation of inferior limbs. It is estimated that 15% of the diabetic population will develop an ulcer sometime in their lives. Although novel therapies have been proposed, there is no effective treatment for this pathology. Naturally produced nitric oxide participates in the wound healing process by stimulating the synthesis of collagen, triggering the release of chemotactic cytokines, increasing blood vessels permeability, promoting angiogenic activity, stimulating the release of epidermical growth factors, and by interfering with the bacterial mitochondrial respiratory chain. Topically administered nitric oxide has demonstrated to be effective and safe for the treatment of chronic ulcers secondary to cutaneous leishmaniasis. However, due to their unstable nitric oxide release, the topical donors needed to be applied frequently, diminishing the adherence to the treatment. This difficulty has led to the development of a multilayer polymeric transdermal patch produced by electrospinning technique that guarantees a constant nitric oxide release. The main objective of this study is to evaluate the effectiveness and safety of this novel nitric oxide releasing wound dressing for the treatment of diabetic foot ulcers.

Methods and design: A double-blind, placebo-controlled clinical trial, including 100 diabetic patients was designed. At the time of enrollment, a complete medical evaluation and laboratory tests will be performed, and those patients who meet the inclusion criteria randomly assigned to one of two groups. Over the course of 90 days group 1 will receive active patches and group 2 placebo patches. The patients will be seen by the research group at least every two weeks until the healing of the ulcer or the end of the treatment. During each visit the healing process of the ulcer, the patient's health status and the presence of adverse events will be assessed. Should the effectiveness of the patches be demonstrated an alternative treatment would then be available to patients.

Trial registration: NCT00428727.

References

    1. World Health Organization Control of hereditary diseases. Report of a WHO Scientific Group Ginebra: WHO Techn Rep Ser 865. 1996. Ref Type: Report.
    1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414–1431.
    1. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746–2753.
    1. Aschner P. Diabetes trends in Latin America. Diabetes Metab Res Rev. 2002;18:S27–S31.
    1. Ministerio de Salud. Centro Nacional de Consultoría III Estudio de Salud bucal – ENSAB III II Estudio Nacional de factores de riesgo de enfermedades crónicas – ENFREC II Tomo V: Prevalencia de diabetes mellitus y glucosa alterada en ayunas. 1999.
    1. Peyrot M, Rubin RR. Levels and risks of depression and anxiety symptomatology among diabetic adults. Diabetes Care. 1997;20:585–590.
    1. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care. 2003;26:1790–1795.
    1. Glasgow RE, Ruggiero L, Eakin EG, Dryfoos J, Chobanian L. Quality of life and associated characteristics in a large national sample of adults with diabetes. Diabetes Care. 1997;20:562–567.
    1. Brod M. Quality of life issues in patients with diabetes and lower extremity ulcers: patients and care givers. Qual Life Res. 1998;7:365–372.
    1. Ashry HR, Lavery LA, Armstrong DG, Lavery DC, van Houtum WH. Cost of diabetes-related amputations in minorities. J Foot Ankle Surg. 1998;37:186–190.
    1. Apelqvist J. Wound healing in diabetes. Outcome and costs. Clin Podiatr Med Surg. 1998;15:21–39.
    1. Reiber GE. The epidemiology of diabetic foot problems. Diabet Med. 1996;13:S6–11.
    1. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE, Wagner EH. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care. 1999;22:382–387.
    1. Kantor J, Margolis DJ. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. Dermatol Surg. 2001;27:347–351.
    1. Boulton AJ. The diabetic foot: a global view. Diabetes Metab Res Rev. 2000;16:S2–S5.
    1. Comparing the incidence of lower extremity amputations across the world: the Global Lower Extremity Amputation Study. Diabet Med. 1995;12:14–18.
    1. Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Davignon DR, Smith DG. A prospective study of risk factors for diabetic foot ulcer. The Seattle Diabetic Foot Study. Diabetes Care. 1999;22:1036–1042.
    1. Frykberg RG, Armstrong DG, Giurini J, Edwards A, Kravette M, Kravitz S, Ross C, Stavosky J, Stuck R, Vanore J. Diabetic foot disorders. A clinical practice guideline. For the American College of Foot and Ankle Surgeons and the American College of Foot and Ankle Orthopedics and Medicine. J Foot Ankle Surg. 2000:1–60.
    1. Consensus Development Conference on Diabetic Foot Wound Care: 7–8 April Boston, Massachusetts. American Diabetes Association. Diabetes Care. 1999;22:1354–1360.
    1. Armstrong DG, Lavery LA. Diabetic foot ulcers: prevention, diagnosis and classification. Am Fam Physician. 1998;57:1325–1328.
    1. Armstrong DG. Is diabetic foot care efficacious or cost effective? Ostomy Wound Manage. 2001;47:28–32.
    1. Dargis V, Pantelejeva O, Jonushaite A, Vileikyte L, Boulton AJ. Benefits of a multidisciplinary approach in the management of recurrent diabetic foot ulceration in Lithuania: a prospective study. Diabetes Care. 1999;22:1428–1431.
    1. Frykberg RG. Team approach toward lower extremity amputation prevention in diabetes. J Am Podiatr Med Assoc. 1997;87:305–312.
    1. Frykberg RG. Diabetic foot ulcers: current concepts. J Foot Ankle Surg. 1998;37:440–446.
    1. Holstein PE, Sorensen S. Limb salvage experience in a multidisciplinary diabetic foot unit. Diabetes Care. 1999;22:B97–103.
    1. Mayfield JA, Reiber GE, Sanders LJ, Janisse D, Pogach LM. Preventive foot care in people with diabetes. Diabetes Care. 1998;21:2161–2177.
    1. Ortegon MM, Redekop WK, Niessen LW. Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis. Diabetes Care. 2004;27:901–907.
    1. Valk GD, Kriegsman DM, Assendelft WJ. Patient education for preventing diabetic foot ulceration. Cochrane Database Syst Rev. 2001:CD001488.
    1. Boulton AJ, Gries FA, Jervell JA. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet Med. 1998;15:508–514.
    1. Edmonds M, Boulton A, Buckenham T, Every N, Foster A, Freeman D, Gadsby R, Gibby O, Knowles A, Pooke M, Tovey F, Unwin N, Wolfe J. Report of the Diabetic Foot and Amputation Group. Diabet Med. 1996;13:S27–S42.
    1. Mayfield JA, Reiber GE, Sanders LJ, Janisse D, Pogach LM. Preventive foot care in diabetes. Diabetes Care. 2004;27:S63–S64.
    1. Nanney LB, Caldwell RL, Pollins AC, Cardwell NL, Opalenik SR, Davidson JM. Novel approaches for understanding the mechanisms of wound repair. J Investig Dermatol Symp Proc. 2006;11:132–139.
    1. Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM) FEMS Immunol Med Microbiol. 1999;26:259–265.
    1. File TM, Jr, Tan JS. Infectious complications in diabetic patients. Curr Ther Endocrinol Metab. 1997;6:491–495.
    1. Calvet HM, Yoshikawa TT. Infections in diabetes. Infect Dis Clin North Am. 2001;15:407–21.
    1. Silhi N. Diabetes and wound healing. J Wound Care. 1998;7:47–51.
    1. Robson MC. The role of growth factors in the healing of chronic wounds. Wound Repair Regen. 1997;5:12–17.
    1. Veves A, Falanga V, Armstrong DG, Sabolinski ML. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001;24:290–295.
    1. Richard JL, Parer-Richard C, Daures JP, Clouet S, Vannereau D, Bringer J, Rodier M, Jacob C, Comte-Bardonnet M. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study. Diabetes Care. 1995;18:64–69.
    1. Faglia E, Favales F, Aldeghi A, Calia P, Quarantiello A, Oriani G, Michael M, Campagnoli P, Morabito A. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. A randomized study. Diabetes Care. 1996;19:1338–1343.
    1. Leslie CA, Sapico FL, Ginunas VJ, Adkins RH. Randomized controlled trial of topical hyperbaric oxygen for treatment of diabetic foot ulcers. Diabetes Care. 1988;11:111–115.
    1. Martinez-de Jesus FR, Morales-Guzman M, Castaneda M, Perez-Morales A, Garcia-Alonso J, Mendiola-Segura I. Randomized single-blind trial of topical ketanserin for healing acceleration of diabetic foot ulcers. Arch Med Res. 1997;28:95–99.
    1. Apelqvist J, Castenfors J, Larsson J, Stenstrom A, Persson G. Ketanserin in the treatment of diabetic foot ulcer with severe peripheral vascular disease. Int Angiol. 1990;9:120–124.
    1. Hogge J, Krasner D, Nguyen H, Harkless LB, Armstrong DG. The potential benefits of advanced therapeutic modalities in the treatment of diabetic foot wounds. J Am Podiatr Med Assoc. 2000;90:57–65.
    1. O'Meara S, Cullum N, Majid M, Sheldon T. Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration. Health Technol Assess. 2000;4:1–237.
    1. Mason J, O'Keeffe C, Hutchinson A, McIntosh A, Young R, Booth A. A systematic review of foot ulcer in patients with Type 2 diabetes mellitus. II: treatment. Diabet Med. 1999;16:889–909.
    1. Weller R, Pattullo S, Smith L, Golden M, Ormerod A, Benjamin N. Nitric oxide is generated on the skin surface by reduction of sweat nitrate. J Invest Dermatol. 1996;107:327–331.
    1. Schaffer MR, Tantry U, Thornton FJ, Barbul A. Inhibition of nitric oxide synthesis in wounds: pharmacology and effect on accumulation of collagen in wounds in mice. Eur J Surg. 1999;165:262–267.
    1. Xiong M, Elson G, Legarda D, Leibovich SJ. Production of vascular endothelial growth factor by murine macrophages: regulation by hypoxia, lactate, and the inducible nitric oxide synthase pathway. Am J Pathol. 1998;153:587–598.
    1. Ghaffari A, Miller CC, McMullin B, Ghahary A. Potential application of gaseous nitric oxide as a topical antimicrobial agent. Nitric Oxide % 2006;14:21–9. Epub.2005.Sep.26.
    1. Lee PC, Salyapongse AN, Bragdon GA, Shears LL, Watkins SC, Edington HD, Billiar TR. Impaired wound healing and angiogenesis in eNOS-deficient mice. Am J Physiol. 1999;277:H1600–H1608.
    1. Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, DiPietro LA. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol. 1998;152:1445–1452.
    1. Stallmeyer B, Kampfer H, Kolb N, Pfeilschifter J, Frank S. The function of nitric oxide in wound repair: inhibition of inducible nitric oxide-synthase severely impairs wound reepithelialization. J Invest Dermatol. 1999;113:1090–1098.
    1. Witte MB, Thornton FJ, Tantry U, Barbul A. L-Arginine supplementation enhances diabetic wound healing: involvement of the nitric oxide synthase and arginase pathways. Metabolism. 2002;51:1269–1273.
    1. Krischel V, Bruch-Gerharz D, Suschek C, Kroncke KD, Ruzicka T, Kolb-Bachofen V. Biphasic effect of exogenous nitric oxide on proliferation and differentiation in skin derived keratinocytes but not fibroblasts. J Invest Dermatol. 1998;111:286–291.
    1. Albina JE, Mills CD, Henry WL, Jr, Caldwell MD. Temporal expression of different pathways of 1-arginine metabolism in healing wounds. J Immunol. 1990;144:3877–3880.
    1. Shabani M, Pulfer SK, Bulgrin JP, Smith DJ. Enhancement of wound repair with a topically applied nitric oxide-releasing polymer. Wound Repair Regen. 1996;4:353–362.
    1. Schaffer MR, Tantry U, Gross SS, Wasserburg HL, Barbul A. Nitric oxide regulates wound healing. J Surg Res. 1996;63:237–240.
    1. Masters KS, Leibovich SJ, Belem P, West JL, Poole-Warren LA. Effects of nitric oxide releasing poly(vinyl alcohol) hydrogel dressings on dermal wound healing in diabetic mice. Wound Repair Regen. 2002;10:286–294.
    1. Witte MB, Kiyama T, Barbul A. Nitric oxide enhances experimental wound healing in diabetes. Br J Surg. 2002;89:1594–1601.
    1. Lopez-Jaramillo P, Ruano C, Rivera J, Teran E, Salazar-Irigoyen R, Esplugues JV, Moncada S. Treatment of cutaneous leishmaniasis with nitric-oxide donor. Lancet. 1998;351:1176–1177.
    1. Silva SY, Rueda LC, Lopez M, Velez ID, Rueda-Clausen CF, Smith DJ, Munoz G, Mosquera H, Silva FA, Buitrago A, Diaz H, Lopez-Jaramillo P. Double blind, randomized controlled trial, to evaluate the effectiveness of a controlled nitric oxide releasing patch versus meglumine antimoniate in the treatment of cutaneous leishmaniasis [NCT00317629] Trials. 2006;7:14.
    1. Hardwick JB, Tucker AT, Wilks M, Johnston A, Benjamin N. A novel method for the delivery of nitric oxide therapy to the skin of human subjects using a semi-permeable membrane. Clin Sci (Lond) 2001;100:395–400.
    1. Smith D, Lopez-Jaramillo P, Lopez M. Nitric Oxide Donor Devices. [WO 2006/058318] 2006. Ref Type: Patent.
    1. Sinnreich M, Taylor BV, Dyck PJ. Diabetic neuropathies. Classification, clinical features, and pathophysiological basis. Neurologist. 2005;11:63–79.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner